As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...
Investor's Business Daily on MSN
These two biotech stocks rocketed — and one just broke out
Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.
Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...
Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity ...
In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...
Top 10 mid-cap stocks by YTD performance amid market volatility—see 600%+ gainers across semis, biotech & more, plus mid-cap ...
Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results